Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.58 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | CTSD | P07339 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799865 | 0.92 | BACE1 (0.61) | BACE1BACE2PTPN1CTSDOPRM1 | |
| SCHEMBL30799637 | 0.92 | BACE1 (0.64) | BACE1BACE2PTPN1OPRM1OPRD1 | |
| SCHEMBL30799423 | 0.92 | BACE1 (0.61) | BACE1BACE2PTPN1OPRM1OPRD1 | |
| SCHEMBL30799576 | 0.90 | BACE1 (0.66) | BACE1BACE2PTPN1CTSD | |
| SCHEMBL30799407 | 0.90 | BACE1 (0.61) | BACE1BACE2PTPN1CTSD | |
| SCHEMBL30799644 | 0.90 | BACE1 (0.57) | BACE1BACE2PTPN1OPRM1OPRD1 | |
| SCHEMBL30799850 | 0.90 | BACE1 (0.61) | BACE1BACE2PTPN1OPRM1OPRD1 | |
| SCHEMBL30833335 | 0.90 | LTA4H (0.61) | BACE1BACE2PTPN1OPRM1OPRD1 | |
| SCHEMBL30833336 | 0.90 | LTA4H (0.61) | BACE1BACE2PTPN1OPRM1OPRD1 | |
| SCHEMBL30799445 | 0.90 | BACE1 (0.61) | BACE1BACE2PTPN1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | BACE1 10/4885BACE2 38/4885PTPN1 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.